Pharmaceutical companies have paid billions of dollars to settle federal allegations of fraud and other wrongdoing in recent years.
In 2009, Eli Lilly and Company agreed to pay a 1.4 billion fine to resolve allegations of off-label promotion of Zyprexa, according to the U.S. Department of Justice (DOJ) website.
In 2012, GlaxoSmithKline agreed to plead guilty and pay a $3 billion fine to resolve fraud allegations and failure to report safety data, the DOJ said.
Continue Reading
Recently, a federal jury ordered Takeda Pharmaceutical Co. and Eli Lilly and Company to pay a total of $9 billion in punitive damages after finding that the companies had concealed cancer risks associated with pioglitazone, a diabetes drug.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.